Investigational Studies

US regulators have assigned GW Pharmaceuticals’ cannabidiol Epidiolex orphan drug designation for the treatment of the rare genetic disorder Tuberous Sclerosis Complex.   TSC causes non-malignant tumours to form in many different organs, with the brain and skin being the most commonly affected tissues. There are around 50,000 in the US and nearly 1 million […]

DEVON, Pa., May 12, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided an overview of recent operational highlights. “We continue to make rapid progress in our ZYN002 cannabidiol (CBD) gel […]

DEVON, Pa., May 12, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided an overview of recent operational highlights. “We continue to make rapid progress in our ZYN002 cannabidiol (CBD) gel […]

Copyright © 2016 Zacks Investment Research At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has nearly tripled the SP 500 […]

LONDON, May 04, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on […]

Copyright © 2016 Zacks Investment Research At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has nearly tripled the SP 500 […]

It’s an exciting week ahead for pharmaceutical companies Relypsa Inc (NASDAQ:RLYP), GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Exelixis, Inc. (NASDAQ:EXEL), as analysts are anticipating these companies’ quarterly reports and sales updates on key drugs. Here is what to watch as each company posts earnings this week: Relypsa Inc The pharmaceutical company is expected to […]

Insys Therapeutics, Inc. (NASDAQ:INSY) Q1 2016 Earnings Conference Call April 28, 2016 10:00 AM ET Executives Ilanit Allen – Investor Relations John Kapoor – Chairman, President and Chief Executive Officer Darryl Baker – Chief Financial Officer Santosh Vetticaden – Chief Medical Officer Analysts Randall Stanicky – RBC Capital Markets David Amsellem – Piper Jaffray Co. […]

by

LONDON, April 28, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 May, 2016 its second quarter and half-year financial results for the period ending 31 March, 2016. GW will […]

by

The FDA designates GW Pharmaceuticals’ (GWPH -0.9%) Epidiolex (cannabidiol) an Orphan Drug for the treatment of Tuberous Sclerosis Complex (TSC), a rare genetic condition characterized by the formation of non-malignant tumors in different organs that frequently cause seizures. Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, […]

by

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). TSC is a rare genetic disorder, the most common symptom […]

by

LONDON, April 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for cannabidiol (CBD) for the treatment of […]

by

Tweet Send this article by email What is your name? Please indicate below the emails to which you want to send this article: The CBD Story Enter one email per line. No more than 5 emails. Send Close 420 special section By Patrick Maravelias | Weed that doesn’t get you high–what a time to be […]

by